Journal article
Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse
Evan S Herrmann, Ziva D Cooper, Gillinder Bedi, Divya Ramesh, Stephanie Collins Reed, Sandra D Comer, Richard W Foltin, Margaret Haney
ADDICTION BIOLOGY | WILEY | Published : 2019
DOI: 10.1111/adb.12664
Abstract
Tobacco and cannabis co-users (T+CUs) have poor cannabis cessation outcomes, but the mechanisms underlying this are not well understood. This laboratory study examined the effects of (1) the partial nicotinic agonist, varenicline, on tobacco cessation among T+CUs, and (2) varenicline, alone, and when combined with the cannabinoid agonist nabilone, on cannabis withdrawal and a laboratory model of cannabis relapse. Non-treatment-seeking T+CUs were randomized to active-varenicline or placebo-varenicline, and completed a 15-day outpatient phase; varenicline was titrated to 1 mg BID during days 1-8, and participants were instructed to abstain from tobacco during days 9-15. Participants then moved..
View full abstractGrants
Awarded by NIDA
Awarded by NATIONAL INSTITUTE ON DRUG ABUSE
Funding Acknowledgements
This project was funded by NIDA R01DA031005, and Dr Herrmann received salary support from NIDA T32DA007294. Dr Haney's research is funded by NIDA. She and Dr Cooper have received partial salary support for an investigator-initiated study from Insys Therapeutics Inc., which did not conflict with this study. Dr Comer has received partial salary support from studies supported by Braeburn Pharmaceuticals, Cerecor, Indivior, MediciNova and Reckitt-Benckiser Pharmaceuticals. In addition, Dr. Comer has served (or will serve) as a consultant to the following companies/organizations over the past 3 years: Advances in Pain Management, AstraZeneca, Clinilabs, Collegium Pharmaceutical, Daiichi Sankyo, Depomed, Egalet, Endo, the Food and Drug Administration, Guidepoint Global, Heptares Therapeutics Limited, Inspirion Delivery Sciences, IntelliPharmaCeutics, Janssen, KemPharm, Mallinckrodt, National Institutes of Health, Neuromed, Opiant, Orexo, Pfizer, Shire and the World Health Organization. None of these responsibilities conflicted with this study. The other authors have no potential conflicts of interest.